ClinicalTrials.gg
Active, not recruitingNCT04075435CBDUpdated Mar 30, 2026

Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia

An Early Phase 1 interventional study of high CBD/low THC sublingual solution in Alzheimer Disease, Anxiety and Agitation,Psychomotor, sponsored by Mclean Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Mclean Hospital · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
1,419th of 1,610
12 · median 73
Started
2021
with 144 others
Phase 1
304 of 1,941
31 open now
Primary completion
2026-12
later than 100 of 443 live
Registered
1,128th of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 1,419th largest by planned enrollment of the 1,610 interventional ones that give a count, is one of 145 that started in 2021, is one of 304 in phase 1, reaches primary completion later than 100 of the 443 other live ones, and was the 1,128th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in individuals with mild cognitive impairment (MCI) or mild to moderate Alzheimer's Disease (AD).

03

Conditions studied

  • Alzheimer Disease
  • Anxiety
  • Agitation,Psychomotor
  • Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease

Keywords

  • cannabidiol
  • older adults
  • dementia
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of probable Alzheimer's Dementia via criteria from McKhann et al., or MCI
  2. score of 15-30 (inclusive)
  3. degree of anxiety, as defined by a Clinical Impression total column score of ≥4 on the Anxiety domain of the NPI-C
  4. A health care proxy available to sign consent on behalf of the participant (if applicable)
  5. A caregiver who spends at least 10 hours per week with the subject who is able to attend all study visits
  6. Participants and their study partner must be fluent in English
  7. Must be 55-90 years old (inclusive)

Exclusion criteria

Exclusion Criteria:

  1. Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease, which might confound assessment of safety outcomes.
  2. Seizure disorder
  3. Lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, as determined by the MINI
  4. Current episode of major depression, as determined by the MINI
  5. Active substance abuse or dependence within the past 6 months, as determined by the MINI
  6. Delirium (as measured by the CAM)
  7. Current inpatient hospitalization
  8. Current regular use of cannabinoid products (>1 use per month)
  9. Positive urine screen for THC at the screening or baseline visit
  10. Allergy to coconut
  11. Participants taking strong inhibitors or inducers of (e.g. fluconazole, fluoxetine, fluvoxamine, ticlopidine, St. John's Wort, etc.), CYP2C19 (ketoconazole, erythromycin, etc.), or anti-epileptic drugs
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Other
    All subjects

    This arm will include all subjects, individuals will administer a high CBD, low THC full spectrum sublingual solution twice daily on a variable dosing schedule.

    Drug: high CBD/low THC sublingual solution

Interventions

  • Drughigh CBD/low THC sublingual solution

    Hemp derived solution to be administered sublingually twice daily.

06

What researchers measure

Primary outcomes

  1. Total of clinician impression column on anxiety domain of the NPI-C

    Measure of Anxiety Domain on the Neuropsychiatric Inventory-Clinician scale

    Time frame: Continuous, weeks 0-8

Secondary outcomes

  1. Total score on the Generalized Anxiety Disorder 7 scale

    Secondary Outcome Measure of anxiety reduction

    Time frame: Continuous, week 0-8

  2. Number of serious adverse events

    Secondary Outcome Measure of safety defined by absence of serious adverse events

    Time frame: Continuous, weeks 0-8

  3. Week 8 MMSE total score compared to baseline MMSE total score

    Secondary Outcome Measure of safety as defined by lack of treatment emergent cognitive impairment as measured by the Mini Mental Status Exam (MMSE)

    Time frame: longitudinal: screening/baseline and week8

  4. Score on the confusion assessment method

    Secondary Outcome Measure of safety defined as absence of treatment emergent delirium as measured by the Confusion Assessment Method (CAM)

    Time frame: Continuous screening weeks 0-8, dichotomous

  5. Number and severity of side effects reported

    Secondary Outcome Measure of safety defined as a low number of emergent somatic side effects as measured by the Medication Side Effects Questionnaire

    Time frame: Continuous, weeks 0-8

Other outcomes

  1. Total clinical impression column score on neuropsychiatric inventory agitation and aggression domains (NPI-C)

    Exploratory measure to see reduction in agitation and aggression symptoms

    Time frame: Continuous, weeks 0-8

  2. Total score of Cohen-Mansfield Inventory (CMAI)

    Exploratory measure to see reduction in agitation symptoms

    Time frame: Continuous, weeks 0-8

  3. Total Score of Zarit Caregiver Burden Interview

    Exploratory downstream reduction in caregiver burden

    Time frame: Continuous, weeks 0-8

  4. Stability of anxiety and agitation reduction using anxiety domain of NPI-C and GAD-7

    Exploratory investigation into the stability of anxiety reduction using the anxiety domain score on the NPI-C and the GAD-7 during the optional follow-up phase

    Time frame: Months 3, 6, 9, and 12 of the optional follow-up phase

  5. Stability of caregiver burden reduction

    Exploratory investigation into reduction of caregiver burden using the Zarit Caregiver Burden Interview during the optional follow-up phase

    Time frame: Months 3, 6, 9, and 12 of the optional follow-up phase

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.

Of 73 non-industry phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 71 months is above that.

Counting every sponsor, half of 236 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2019
First posted
Aug 30, 2019
StartActual
Jan 11, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04075435
Lead sponsor
Mclean Hospital
Collaborators
Spier Family Foundation
Responsible party
Staci Gruber, Ph.D. (Directory, Cognitive and Clinical Neuroimaging Core; Director, Marijuana Investigations for Neuroscientific Discovery (MIND), Mclean Hospital) — Principal investigator
First posted
Aug 30, 2019
Start date
Jan 11, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 30, 2026

Study contacts

Staci Gruber, PhD
principal investigator · Mclean Hospital
Ipsit V Vahia, MD
principal investigator · Mclean Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion